Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Patients (Pts) with advanced NSCLC from Korea treated with pembrolizumab (Pembro) in KEYNOTE-001

Date

20 Dec 2015

Session

Poster presentation 2

Presenters

Jong-Seok Lee

Citation

Annals of Oncology (2015) 26 (suppl_9): 125-147. 10.1093/annonc/mdv532

Authors

J. Lee1, D.H. Lee2, B. Piperdi3, J. Zhang4, G.M. Lubiniecki3, M.A. Ahn5

Author affiliations

  • 1 Hematology/oncology, Seoul National University, Bundang Hospital, 463-707 - Seoul/KR
  • 2 Oncology, Asan Medical Center, Seoul/KR
  • 3 Clinical Oncology, Merck & Co., Inc., Kenilworth/US
  • 4 Bards, Merck & Co., Inc., Kenilworth/US
  • 5 Medicine, Samsung Medical Center, Seoul/KR
More

Resources

Abstract 1035

Aim/Background

In the multicohort, phase 1B KEYNOTE-001 study, the anti–PD-1 antibody pembro provided a 19.4% ORR in 495 pts with previously treated or treatment-naive NSCLC; ORR was 45.2% in pts with membranous PD-L1 expression in ≥50% of tumor cells (tumor proportion score [TPS] ≥50%). We present data for the 22 pts with previously treated NSCLC from Korea enrolled in KEYNOTE-001.

Methods

Pts received pembro 10 mg/kg Q3W (n = 14) or 10 mg/kg Q2W (n = 8) until confirmed progression, intolerable toxicity, or investigator decision. Response was assessed every 9 wk per RECIST v1.1 by central review. PD-L1 expression in tumors was assessed by immunohistochemistry using a clinical trial assay. Pts were evaluable for PD-L1 only if tumor slides were prepared within 6 mo of staining and a PD-L1 TPS could be assigned.

Results

Median age was 60.5 y (range 41-80), 77.3% of pts were men, 77.3% were former smokers, 63.6% had nonsquamous histology, and 18.2% had EGFR mutation. All pts received ≥1 prior therapy, including 31.8% who received ≥4 prior therapies. Nine (40.9%) pts experienced ≥1 treatment-related AE, only 1 of whom experienced events of grade ≥3 severity (grade 4 cardiac tamponade and grade 3 elevated ALT and bilirubin). One case of pneumonitis (grade 2 severity) was reported. No pts experienced treatment-related death or discontinued for a treatment-related AE. ORR was 27.3% overall and 75.0% in pts with TPS ≥50% (Table). At data cutoff, 4 of 6 (66.7%) responders were alive, progression free, and without new anticancer treatment; median duration of response was not reached (NR) (range 2.3+ to 6.6+ mo). Median PFS was 4.2 mo (95% CI 2.0-NR), and the 6-mo PFS rate was 40.9%. The 6-mo OS rate was 77.3%; median OS was NR (95% CI 7.0 mo-NR).

Antitumor Activity by PD-L1 TPS (*includes 11 pts for whom a PD-L1 TPS could not be assigned)

End Point Total N = 22* PD-L1 TPS ≥50% n = 4 PD-L1 TPS 1-49% n = 5 PD-L1 TPS <1% n = 2
ORR, % (95% CI) 27.3 (10.7-50.2) 75.0 (19.4-99.4) 20.0 (0.5-71.6) 0.0 (0.0-84.2)
DCR, % (95% CI) 68.2 (45.1-86.1) 75.0 (19.4-99.4) 60.0 (14.7-94.7) 100.0 (15.8-100.0)

Conclusions

As was found in the overall KEYNOTE-001 NSCLC population, pembro has a manageable safety profile and provides robust, durable antitumor activity in pts from Korea with previously treated NSCLC, particularly those with PD-L1 TPS ≥50%.

Clinical trial identification

NCT01295827

Disclosure

B. Piperdi: current employee of Merck & Co., Inc. Owns stock in Merck & Co., Inc. J. Zhang, G.M. Lubiniecki: employee of Merck & Co., Inc. M.-J. Ahn: Advisory board member for AstraZeneca, Eli Lilly, and Boehringer Ingelheim. All other authors have declared no conflicts of interest.

Resources from the same session

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings